About admin

This author has not yet filled in any details.
So far admin has created 52 blog entries.

Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

By | November 3rd, 2016|Medical publications|0 Comments

Prostate Cancer Blood Test

Schütz, E., et al. Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. Clinical Chemistry 2015; 61: 239-248.

Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.

By | November 3rd, 2016|Medical publications|0 Comments

Rectal Cancer Treatment Outcome Predictions

Beck, J. et al. Comprehensive analyses of rectal cancer genomes to reveal copy number variations as potential predictor of induction therapy efficacy. J ClinOncol 32, 2014 (suppl; abstr e14549).

Genome profiling of individual tumors is provided by high-throughput sequencing and is about to enter routine clinical practice with impact on treatment decisions and tumor classification (NIH [2014] The Cancer Genome Atlas).

By | November 3rd, 2016|Medical publications|0 Comments

HPV Genotyping and Treatment Outcome Predictions

Urnovitz, HB et al. Detection of novel HPV mutations and chromosomal number imbalance (CNI) in laryngeal cancer using next-generation sequencing (NGS). J ClinOncol 32:5s, 2014 (suppl; abstr 6072).

The detection of novel HPV mutations and CNI analysis in a single NGS run on HPV-related diseases provides important information into viral-host dynamics while generating biomarkers that can be correlated with treatment outcomes.

By | November 3rd, 2016|Medical publications|0 Comments

Breast Cancer Liquid Biopsy Screening Test

Beck, J. et al. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. J ClinOncol 31, 2013 (suppl; abstr 11013).

Using comparative massive parallel sequencing of cfDNA from cancer patients vs. controls, we were able to show that a 16-region model based on CNV, is useful to distinguish patients with breast cancer from matched controls.

By | November 3rd, 2016|Medical publications|0 Comments

Minimal Residual Disease in Breast Cancer

Urnovitz, HB et al. Modulation of breast cancer cell-free DNA with surgical resection. J ClinOncol 31, 2013 (suppl; abstr 11060).

In this study, we sought to determine whether cfDNA decreases after surgery in patients with operable invasive breast cancer. Serum was collected before and 1-4 weeks after surgery from 16 breast cancer patients and also from 24 age and gender matched controls.

By | November 3rd, 2016|Medical publications|0 Comments

NGS Animal Model for MRD in Breast Cancer

Beck, J. et al. Structural variation in mammary carcinomas and their detection in cell-free plasma DNA. PLOS One 2013 (10.1371/journal.pone.0075485).

Mammary tumors are the most frequent cancers in female dogs exhibiting a variety of histopathological differences. There is lack of knowledge about the genomes of these common dog tumors. Five tumors of three different histological subtypes were evaluated.

By | November 3rd, 2016|Medical publications|0 Comments

NGS of prostate cancer

Schütz, E. et al. Comparative analysis of the chromosomal origins of circulating nucleic acids in breast and prostate cancer. J ClinOncol 28:15s, 2010 (suppl; abstr 10505).

The aim of this study was to find signature CNA sequences from patients with breast cancer (BCa) or prostate cancer (PCa) compared to healthy controls, with respect to their predictive potential, as well as to provide new insights into tumor biology.

By | November 3rd, 2016|Medical publications|0 Comments

Breast Cancer cfDNA with NGS

Beck, J. et al. Next Generation Sequencing of Serum Circulating Nucleic Acids from Invasive Ductal Breast Cancer Patients Reveals Differences to Healthy and Non-malignant Controls. Mol. Cancer Res. 2010; 8: 385-92.

Circulating nucleic acids (CNA) isolated from serum or plasma are increasingly recognized as biomarkers for cancers.We report specific DNA-transposable element sequences that could discriminate all stages of invasive ductal breast carcinoma with significant specificity and sensitivity.

By | November 3rd, 2016|Medical publications|0 Comments

NGS of cell-free DNA in Healthy Humans

Beck, J. et al. Profile of the circulating DNA in apparently healthy individuals. Clin Chem. 2009; 55: 730-8.

Circulating nucleic acids (CNAs) have been shown to have diagnostic utility in human diseases. The use of mass sequencing and bioinformatics provides the basis for new diagnostic approaches that use CNAs as biomarkers for both malignant and nonmalignant diseases.

By | November 3rd, 2016|Medical publications|0 Comments